Swedish industrial technology company Indutrade AB posted a notable improvement in quarterly results, with net profit for April through June rising to SEK 784 million from SEK 639 million a year earlier, reflecting a 23% increase. The company attributed the improvement to firmer industrial demand, record order intake and higher operating margins.
Operating profit climbed 19% to SEK 1.13 billion, while EBITA increased 19% to SEK 1.32 billion. The EBITA margin improved to 14.7% from 13.7% in the prior-year period, underscoring improved profitability across the group's businesses.
Indutrade reported net sales of SEK 8.99 billion, up 11% versus the same quarter a year earlier. Comparable organic sales growth was 5%. The quarter also delivered stronger per-share results, with diluted earnings per share rising to SEK 2.15 from SEK 1.75.
Order intake reached a record SEK 9.41 billion, a 14% increase and above the level of net sales for the quarter. Management highlighted that order backlog has been strengthened, providing a solid foundation as the company moves into the second half of the year.
The company said demand recovered across a number of end markets following a period of subdued activity. Higher activity in medical technology, pharmaceuticals and energy were specifically noted as contributors to organic growth during the quarter.
Acquisitions remain a central part of Indutrade's strategy. The group completed five acquisitions in the quarter and has bought nine companies so far this year, with those deals representing combined annual sales of about SEK 1.5 billion. Management presented this acquisition activity as supporting its longer-term, acquisition-driven growth approach.
While the firm expressed confidence in its positioning - pointing to structurally growing end markets, a robust order book and a diversified business model - it acknowledged that geopolitical tensions and macroeconomic uncertainty continue to cloud the broader outlook. Despite those headwinds, the company said it was well positioned for the remainder of 2026.
Context for markets and sectors
- Industrial technology and manufacturing supply chains are central to the results, with demand improvements driving sales and orders.
- Medical technology, pharmaceuticals and energy segments were cited as particular sources of higher activity for the quarter.
- Continued M&A activity contributes to the company’s growth trajectory and expands its revenue base.